NOVO.B.DK

467.05

-3.24%↓

COLO.B.DK

697

-4.49%↓

GMAB.DK

1,282.5

-1.84%↓

HLUNB.DK

31.52

-6.69%↓

AMBUB.DK

114.2

-4.11%↓

NOVO.B.DK

467.05

-3.24%↓

COLO.B.DK

697

-4.49%↓

GMAB.DK

1,282.5

-1.84%↓

HLUNB.DK

31.52

-6.69%↓

AMBUB.DK

114.2

-4.11%↓

NOVO.B.DK

467.05

-3.24%↓

COLO.B.DK

697

-4.49%↓

GMAB.DK

1,282.5

-1.84%↓

HLUNB.DK

31.52

-6.69%↓

AMBUB.DK

114.2

-4.11%↓

NOVO.B.DK

467.05

-3.24%↓

COLO.B.DK

697

-4.49%↓

GMAB.DK

1,282.5

-1.84%↓

HLUNB.DK

31.52

-6.69%↓

AMBUB.DK

114.2

-4.11%↓

NOVO.B.DK

467.05

-3.24%↓

COLO.B.DK

697

-4.49%↓

GMAB.DK

1,282.5

-1.84%↓

HLUNB.DK

31.52

-6.69%↓

AMBUB.DK

114.2

-4.11%↓

Search

Zealand Pharma A-S

Avatud

457.8 -5.69

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

446

Max

484.6

Põhinäitajad

By Trading Economics

Sissetulek

-25M

-291M

Müük

4.6M

9.1M

Aktsiakasum

-4.12

Kasumimarginaal

-3,213.715

Töötajad

335

EBITDA

8.1M

-253M

Soovitused

By TipRanks

Soovitused

Neutraalne

12 kuu keskmine prognoos

+25.15% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

15. mai 2025

Turustatistika

By TradingEconomics

Turukapital

-13B

37B

Eelmine avamishind

463.49

Eelmine sulgemishind

457.8

Zealand Pharma A-S Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

12. märts 2025, 09:23 UTC

Suurimad hinnamuutused turgudel

Zealand Pharma Shares Leap After Weight-Loss Licensing Deal With Roche

20. dets 2024, 09:22 UTC

Suurimad hinnamuutused turgudel

Zealand Pharma Shares Fall After FDA Pushes Back Bowel-Disease Drug

12. märts 2025, 16:34 UTC

Peamised uudised

Roche, Zealand Pharma Strike $5.3 Billion Weight-Loss Therapy Deal -- Update

12. märts 2025, 08:18 UTC

Market Talk

Roche's Obesity Deal With Zealand Pharma Makes Sense, Vontobel Says -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Zealand Pharma A-S Prognoos

Hinnasiht

By TipRanks

25.15% tõus

12 kuu keskmine prognoos

Keskmine 270.582 DKK  25.15%

Kõrge 270.568 DKK

Madal 270.568 DKK

Põhineb 1 Wall Streeti analüütiku instrumendi Zealand Pharma A-S 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

1 ratings

0

Osta

1

Hoia

0

Müü

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Zealand Pharma A-S

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon that is in Phase III clinical trials for treating congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark.